JP2007526756A5 - - Google Patents

Info

Publication number

JP2007526756A5

JP2007526756A5 JP2006522632A JP2006522632A JP2007526756A5 JP 2007526756 A5 JP2007526756 A5 JP 2007526756A5 JP 2006522632 A JP2006522632 A JP 2006522632A JP 2006522632 A JP2006522632 A JP 2006522632A JP 2007526756 A5 JP2007526756 A5 JP 2007526756A5

Authority

JP

Japan

Prior art keywords

cdr

antibody

amino acid

acid sequence

seq

Prior art date

2004-07-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 claims description 58
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 54
• 102000058223 human VEGFA Human genes 0.000 claims description 53
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 43
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 43
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 42
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 42
• 108091008605 VEGF receptors Proteins 0.000 claims description 24
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 24
• 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 claims description 19
• 238000000034 method Methods 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 6
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 5
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 claims description 3
• 239000004229 Alkannin Substances 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 66
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 58
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 58
• 239000003814 drug Substances 0.000 claims 14
• 239000012472 biological sample Substances 0.000 claims 5
• 201000010099 disease Diseases 0.000 claims 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 241000124008 Mammalia Species 0.000 claims 3
• 206010030113 Oedema Diseases 0.000 claims 3
• 150000007523 nucleic acids Chemical class 0.000 claims 3
• 102000039446 nucleic acids Human genes 0.000 claims 3
• 108020004707 nucleic acids Proteins 0.000 claims 3
• 206010048962 Brain oedema Diseases 0.000 claims 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
• 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
• 210000004369 blood Anatomy 0.000 claims 2
• 239000008280 blood Substances 0.000 claims 2
• 208000006752 brain edema Diseases 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 239000012530 fluid Substances 0.000 claims 2
• 208000026278 immune system disease Diseases 0.000 claims 2
• 208000027866 inflammatory disease Diseases 0.000 claims 2
• 230000000250 revascularization Effects 0.000 claims 2
• 210000002966 serum Anatomy 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• 210000001519 tissue Anatomy 0.000 claims 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims 1
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 206010009944 Colon cancer Diseases 0.000 claims 1
• 206010012646 Diabetic blindness Diseases 0.000 claims 1
• 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
• 238000009007 Diagnostic Kit Methods 0.000 claims 1
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
• 206010027406 Mesothelioma Diseases 0.000 claims 1
• 241001529936 Murinae Species 0.000 claims 1
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
• 206010060862 Prostate cancer Diseases 0.000 claims 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
• 201000004681 Psoriasis Diseases 0.000 claims 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
• 206010038389 Renal cancer Diseases 0.000 claims 1
• 208000017442 Retinal disease Diseases 0.000 claims 1
• 206010038923 Retinopathy Diseases 0.000 claims 1
• 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
• 206010064930 age-related macular degeneration Diseases 0.000 claims 1
• 230000000259 anti-tumor effect Effects 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 238000004113 cell culture Methods 0.000 claims 1
• 239000006143 cell culture medium Substances 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 208000029742 colonic neoplasm Diseases 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 239000002254 cytotoxic agent Substances 0.000 claims 1
• 231100000599 cytotoxic agent Toxicity 0.000 claims 1
• 238000001514 detection method Methods 0.000 claims 1
• 201000002595 endometriosis of ovary Diseases 0.000 claims 1
• 201000010536 head and neck cancer Diseases 0.000 claims 1
• 208000014829 head and neck neoplasm Diseases 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 201000010982 kidney cancer Diseases 0.000 claims 1
• 201000010260 leiomyoma Diseases 0.000 claims 1
• 201000007270 liver cancer Diseases 0.000 claims 1
• 208000014018 liver neoplasm Diseases 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 201000001441 melanoma Diseases 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 201000000050 myeloid neoplasm Diseases 0.000 claims 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
• 208000030747 ovarian endometriosis Diseases 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 239000000523 sample Substances 0.000 claims 1
• 238000012216 screening Methods 0.000 claims 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 description 24
• 108090000765 processed proteins & peptides Proteins 0.000 description 23
• 235000004279 alanine Nutrition 0.000 description 22
• 229920001184 polypeptide Polymers 0.000 description 22
• 102000004196 processed proteins & peptides Human genes 0.000 description 22
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 20
• 230000035772 mutation Effects 0.000 description 20
• 108020004705 Codon Proteins 0.000 description 17
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 235000001014 amino acid Nutrition 0.000 description 12
• 238000006467 substitution reaction Methods 0.000 description 11
• 230000001627 detrimental effect Effects 0.000 description 8
• 241000699660 Mus musculus Species 0.000 description 7
• 238000011580 nude mouse model Methods 0.000 description 7
• 230000004614 tumor growth Effects 0.000 description 7
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 229940120638 avastin Drugs 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 231100000219 mutagenic Toxicity 0.000 description 4
• 230000003505 mutagenic effect Effects 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 230000003442 weekly effect Effects 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 210000004027 cell Anatomy 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 102220202173 rs148450358 Human genes 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 1
• 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1